GaëlSaint Olive

Associé

Paris + 33.1.56.59.39.39

Spécialisé en fusions-acquisitions, Gaël Saint Olive conseille des clients français et internationaux dans le cadre de leurs fusions-acquisitions transfrontalières et joint ventures, notamment lors d’opérations multi-juridictionnelles impliquant la coordination d’équipes juridiques situées dans plusieurs pays.

Gaël Saint Olive a ainsi conseillé Sanofi dans le cadre de la création d'une joint venture avec Lonza, la vente de diverses activités pharmaceutiques mondiales ou multinationales, la dissolution d'une joint venture européenne avec Merck, la cession d'une filiale en Afrique, l'acquisition d'un leader des génériques en Colombie et l'acquisition d'actifs pharmaceutiques en Afrique.

Parmi les clients conseillés par Gaël Saint Olive, on peut citer : Solvay dans le cadre de la cession d'une de ses divisions européennes à Imerys, Henderson Park dans le cadre du rachat de l'Hôtel Méridien, Simon Property Group lors de sa prise de participation de 27,8% dans Klépierre, Société de Financement Local (SFIL) lors de sa création à la suite du désengagement de Dexia Crédit Local des marchés, la Caisse des Dépôts et Consignations dans le cadre de plusieurs partenariats public-privé, ainsi que le High Museum of Art d’Atlanta dans le cadre de son partenariat avec le Musée du Louvre.

Expérience

  • Sanofi sells 10 established products to CheplapharmJones Day is advising Sanofi in the sale of a portfolio of pharmaceutical products to Cheplapharm Arzneimittel GmbH, a German privately-owned company headquartered in Greifswald, Germany.
  • Sanofi divests 16 brands to STADAJones Day advised Sanofi in the sale of 16 Consumer Healthcare products commercialized in Europe to STADA Arzneimittel AG.
  • Sanofi sells anti-inflammatory drugs to Fidia FarmaceuticiJones Day advised Sanofi in the sale of a portfolio of pharmaceutical products to Fidia Farmaceutici.
  • Solvay sold Process Materials business to Composites OneJones Day advised Solvay S.A., a publicly listed chemical company based in Brussels, Belgium, in the sale of its Process Materials business, to Composites One, the leading North American supplier of composites materials and value added services.
  • Astellas returns rights to Eligard® in Europe, Middle East, CIS, and Asia to TolmarJones Day represented Astellas Pharma Europe Ltd. in connection with a series of transactions, including the sale of related assets, in which Astellas returned its in-licensing rights to Eligard® (leuprorelin acetate for injectable suspension), a treatment for advanced prostate cancer, sold by Astellas in Europe, the Middle East, the Commonwealth of Independent States (CIS) and Asia, to Tolmar International Limited.
  • Sanofi sold Effortil (Etilefrin) pharmaceuticals products to SERB SAJones Day advised Sanofi in the sale of the Effortil (Etilefrin) pharmaceuticals products to SERB SA.
  • Sanofi sold "Biopark by Sanofi" to Evotec SEJones Day advised Sanofi in the sale of "Biopark by Sanofi" to Evotec SE.
  • Sanofi sold Lepticur to Laboratoires DelbertJones Day advised Sanofi in the sale of Lepticur to Laboratoires Delbert.
  • Sanofi sold two product portfolios to CHEPLAPHARMJones Day advised Sanofi in the sale of a portfolio of pharmaceuticals products to CHEPLAPHARM Arzneimittel GmbH.
  • Government of the Republic of Togo privatizes telecommunications companyJones Day advised the Government of the Republic of Togo on an international bidding procedure to privatize TogoCom.
  • Sanofi sells infectious disease unit to EvotecJones Day advised Sanofi in the sale of its infectious disease unit to Evotec AG.
  • Sanofi sells over-the-counter portfolio to Charterhouse for €158 million (US$195 million)Jones Day advised Sanofi SA in its €158 million (US$195 million) sale of a portfolio of 12 over-the-counter pharmaceuticals products to an affiliate of the Cooper-Vemedia group, a subsidiary of Charterhouse Capital Partners LLP group.
  • Vivendi sells stake in Ubisoft Entertainment for approximately €2 billionJones Day advised Crédit Agricole Corporate and Investment Bank (CACIB) in connection with the sale by Vivendi of its stake in Ubisoft Entertainment (Ubisoft) for approximately €2 billion.
  • Campus Agro leads AgroParisTech-INRA campus project in SaclayJones Day advised Caisse des Depots et Consignations (CDC), as shareholder of Campus Agro SAS (a company created by AgroParisTech, INRA, and CDC), on a project including (i) a public-public partnership and (ii) a public-private partnership (€257 million) lasting for 30 years with a consortium led by GTM Bâtiment (VINCI group) and ENGIE Cofely. The consortium will design, build, maintain, and operate the new AgroParisTech-INRA campus in Saclay.
  • Sanofi and Lonza form joint venture to establish large-scale biologics production facility in SwitzerlandJones Day advised Sanofi in the formation of a joint venture with Lonza Group AG to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
  • Sanofi dissolves joint venture with MerckJones Day advised Sanofi in the dissolution of a 22 year old pan European joint venture with Merck & Co.
  • Henderson Park buys Le Méridien Etoile Hotel, the largest hotel in Paris, for €365 million (US$392 million)Jones Day advised Henderson Park Real Estate Fund I on its acquisition and first mortgage financing of Le Méridien Etoile Hotel, the largest hotel in Paris, which was sold by a partnership of Mount Kellett Capital Management and Cedar Capital Partners, for €365 million (US$392 million).
  • Atlas Holdings completes first phase of purchase of NCR Corporation's Interactive Printer Solutions DivisionJones Day represented affiliates of Atlas Holdings, LLC in its acquisition of the Interactive Printer Solutions ("IPS") division of NCR Corporation.
  • Solvay divests its PCC business to ImerysJones Day advised Solvay in the divestiture of its PCC (precipitated calcium carbonates) business to Imerys.
  • Cardinal Health acquires Cordis for $1.9 billionJones Day advised Cardinal Health, Inc. in its acquisition of Johnson & Johnson's Cordis business, a leading global manufacturer of cardiology and endovascular devices, for $1.9 billion in cash.
  • Autres publications

    • March 20, 2006
      Dépénalisation, vous avez dit dépénalisation ?, Option Finance

    Interventions

    • 12 avril 2018
      Finale de la 4ème édition du Prix Jones Day/Paris II/ESSEC
    • 20 avril 2017
      Finale de la 3ème édition du Prix Jones Day/ESSEC/Paris II
    • 24 mai 2016
      Réforme du droit des contrats et du droit des obligations - 1er volet : quel impact pour vos opérations M&A ?